Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Aminomonosaccharide; in Spain glucosamine sulphate is registered as a prescription medicine for knee osteoarthritis, supplements more often contain the hydrochloride; marketed as a chondroprotective agent

Updated · Methodology

Mechanism

The acenocoumarol and glucosamine summaries of product characteristics (SmPCs) report a raised international normalised ratio (INR) in people taking glucosamine with oral vitamin K antagonists (acenocoumarol and glucosamine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is a vitamin K antagonist (acenocoumarol SmPC, AEMPS). The documents do not describe the mechanism. Data on glucosamine interactions are limited. The absorption, distribution, metabolism and excretion of glucosamine are not fully understood, and its mechanism of action in humans is unknown (glucosamine SmPC, AEMPS).

Symptoms

The main risk is bleeding from a rise in the international normalised ratio (INR), which has been reported with glucosamine and vitamin K antagonists (acenocoumarol and glucosamine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS). Tachycardia, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain can also occur (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. In patients taking acenocoumarol, monitor coagulation closely when glucosamine is started and when it is stopped (acenocoumarol and glucosamine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Whenever any drug is added or stopped, use close and frequent coagulation checks, for example twice a week (acenocoumarol SmPC, AEMPS). Glucosamine is not indicated for acute pain. Relief usually appears within the first 4 weeks. If there is none after 2–3 months, reconsider continuing glucosamine (glucosamine SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose of acenocoumarol is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. Restart acenocoumarol once the INR is back in the target range (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol